Biotheus (普米斯生物技术) is a biotech company that develops antibody-based therapeutics for cancer and metabolic disease. Its R&D capabilities include antibody discovery, process development, and analytical assessment platforms. The company also studies the mechanisms of Treg cells and innate immunity in cancer.
Biotheus has raised $114.5 million in total funding. Investors of Biotheus include Huajin Capital, Shiyu Capital, HighLight Capital, New Alliance Capital, General Atlantic and 8 more.
Biotheus has raised $114.5 million in total funding. Investors of Biotheus include Huajin Capital, Shiyu Capital, HighLight Capital, New Alliance Capital, General Atlantic and 8 more.
Location: China
Investors 1
| Date | Name | Website |
| - | New Allian... | nac-capita... |
Mentions in press and media 8
| Date | Title | Description |
| 31.07.2025 | Pandemic darlings Moderna, BioNTech are now on two different paths | Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA technology and BioNTech pursuing deals t... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong. In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 17.07.2025 | Sino Biopharm to Buy Out LaNova for Up to USD951 Million, Heralding Potential M&A Wave | (Yicai) July 17 -- Sino Biopharmaceutical said it plans to spend as much as USD951 million to fully acquire LaNova Medicines, a move that may point to more mergers and acquisitions in the Chinese drugs industry. Sino Biopharm will buy the 9... |
| 15.03.2024 | Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates | ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceut... |
| 06.11.2023 | Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications | Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM80... |
| 20.07.2023 | Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech | ZHUHAI, China, July 20, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, announced today that it has ... |
| 15.11.2022 | Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory | ZHUHAI, China, Nov. 15, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collabo... |
| 03.12.2021 | Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies | ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conductin... |